Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren Hodgson

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Reply to S. SorscherJames Hadfield, Chris Abbosh, Darren Hodgson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?Dan Stetson, Paul Labrousse, Hugh Russell, et al.
BMC Cancer|January 4, 2022
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasetsZhongwu Lai, Matthew Brosnan, Ethan S Sokol, et al.
JCO Precision Oncology|October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of TreatmentAleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Trends in Cancer|June 5, 2024
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancerChris Abbosh, Darren Hodgson, Gary J Doherty, et al.
JCO Precision Oncology|May 21, 2026
Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?Yiqing Zhao, John Gallon, Max H Kushner, et al.
Cancer Biomarkers : Section a of Disease Markers|November 19, 2015
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancerHiroyuki Nomura, Fumio Kataoka, Daisuke Aoki, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2025
Clinicopathological Predictors of the Presence of Blood Circulating Tumor DNA in Early-Stage Non-Small Cell Lung CancersArnaud Driussi, Fabien C Lamaze, Manal Kordahi, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|January 19, 2013
Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patientsHee Sung Kim, Min A Kim, Darren Hodgson, et al.
Cancer Letters|May 26, 2024
Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancerYohan Bossé, Abhijit Dasgupta, Michael Abadier, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Reply to S. SorscherJames Hadfield, Chris Abbosh, Darren Hodgson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?Dan Stetson, Paul Labrousse, Hugh Russell, et al.
BMC Cancer|January 4, 2022
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasetsZhongwu Lai, Matthew Brosnan, Ethan S Sokol, et al.
JCO Precision Oncology|October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of TreatmentAleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Trends in Cancer|June 5, 2024
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancerChris Abbosh, Darren Hodgson, Gary J Doherty, et al.
JCO Precision Oncology|May 21, 2026
Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?Yiqing Zhao, John Gallon, Max H Kushner, et al.
Cancer Biomarkers : Section a of Disease Markers|November 19, 2015
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancerHiroyuki Nomura, Fumio Kataoka, Daisuke Aoki, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2025
Clinicopathological Predictors of the Presence of Blood Circulating Tumor DNA in Early-Stage Non-Small Cell Lung CancersArnaud Driussi, Fabien C Lamaze, Manal Kordahi, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|January 19, 2013
Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patientsHee Sung Kim, Min A Kim, Darren Hodgson, et al.
Cancer Letters|May 26, 2024
Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancerYohan Bossé, Abhijit Dasgupta, Michael Abadier, et al.
Pageof 3